GleamWall
中文EN

NRSN NeuroSense Therapeutics Ltd. Annual reports only

Pharmaceutical Preparations · Nasdaq · SEC CIK 1875091 · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY—
TTM net income YoY-9.0%
TTM EPS YoY18.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-2,175.0%
ROA-397.1%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets251.8%
Debt / equity—
Current ratio0.31x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.69x
Accruals ratio-123.3%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Annual Quarterly (none) Export CSV 🔒
Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$6.23M$5.70M
SG&A expense$4.86M$4.20M
Operating income-$11.09M-$9.90M
Net income-$11.12M-$10.21M
EBITDA-$11.07M-$9.88M
EPS (basic)-0.44-0.54
EPS (diluted)-0.44-0.54
Weighted avg. shares (diluted)25.48M18.60M
Balance sheet
Cash & equivalents$166,000$3.38M
Current assets$778,000$4.40M
PP&E, net$58,000$66,000
Total assets$1.03M$4.58M
Current liabilities$2.52M$1.99M
Total liabilities$2.59M$1.99M
Shareholders' equity-$1.56M$2.58M
Shares outstanding32.56M23.23M
Cash flow statement
Operating cash flow-$7.67M-$10.13M
Capital expenditure$8,000$3,000
Free cash flow-$7.68M-$10.14M
Investing cash flow-$8,000$1,000
Financing cash flow$4.43M$10.91M
Depreciation & amortization$16,000$22,000
Stock-based compensation$2.14M$557,000

Free plan shows the latest 2 periods; Pro shows all 7 🔒

· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.